UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
_______________
FORM 8-K/A
CURRENT REPORT
Date of report (Date of earliest event reported): June 16, 2003
La Jolla Pharmaceutical Company
(Exact Name of Registrant as Specified in Charter)
| Delaware | 0-24274 | 33-0361285 | ||
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| 6455 Nancy Ridge Drive, San Diego, California (Address of Principal Executive Offices) |
92121 (Zip Code) |
Registrant’s telephone number, including area code: (858) 452-6600
| ITEM 5. OTHER EVENTS | ||||||||
| ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS. | ||||||||
| SIGNATURES | ||||||||
| EXHIBIT 99.1 | ||||||||
Explanatory Note: This Form 8-K/A and the related Press Release filed herewith as Exhibit 99.1 is filed to correct information in the third sentence of the fifth paragraph of the Press Release as previously filed.
ITEM 5. OTHER EVENTS
On June 16, 2003, the Company issued a press release announcing, among other matters, the health-related quality of life results from the Riquent™ Phase 3 trial. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
The following exhibits are filed with this report on Form 8-K:
| Exhibit | ||
| Number | Description of Exhibit | |
| 99.1 | Press Release |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| LA JOLLA PHARMACEUTICAL COMPANY | ||||
| Date: August 1, 2003 | By: | /s/ Steven B. Engle | ||
| Steven B. Engle Chairman and Chief Executive Officer |
||||
3